stockrowImmunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
Follow IMNM
Alert me
Immunome, Inc. (IMNM) Current ratio
Immunome, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 15.1×, up 0.4× from fiscal 2025 (14.7×). Over the past ten years it has ranged from 1.4× (fiscal 2018) to 14.7× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 14.7× | 260.36% |
| FY2024 | 4.1× | (38.52%) |
| FY2023 | 6.6× | 114.56% |
| FY2022 | 3.1× | (46.94%) |
| FY2021 | 5.8× | (58.76%) |
| FY2020 | 14.1× | 652.98% |
| FY2019 | 1.9× | 38.66% |
| FY2018 | 1.4× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 15.1× | (30.46%) |
| Mar 2026 | 21.7× | 47.62% |
| Dec 2025 | 14.7× | 64.99% |
| Sep 2025 | 8.9× | (26.59%) |
| 22 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 32.8× |
| PVLA Palvella Therapeutics, Inc. compare | 21.2× |
| IMNM Immunome, Inc. | 15.1× |
| CLDX Celldex Therapeutics, Inc. compare | 11.8× |
| VERA Vera Therapeutics, Inc. compare | 10.9× |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.1× |
| ADMA ADMA Biologics Inc compare | 6.0× |
| VCEL Vericel Corporation compare | 5.1× |
| BHVN Biohaven Ltd. compare | 3.1× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on IMNM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement